UNSPSC 51435001: Amlodipine/atorvastatin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV200. This VA Drug Class (CV200) classifies this compound as belonging to the group CALCIUM CHANNEL BLOCKERS.

UNSPSC 51435001 Amlodipine/atorvastatin is a Commodity code under which state and local governments procure emergency medical and pharmaceutical supplies for public health agencies, fire rescue services, and health benefit programs. Recent solicitations show demand for Advanced Life Support medications supplied to emergency services, generic pharmaceuticals distributed through state cooperative purchasing networks, and direct-to-manufacturer prescription programs managed by state health agencies. The issuing bodies include city purchasing departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). Vendors in this space must navigate expiration-date requirements, FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, Safety Data Sheets documentation, and insurance requirements including commercial general liability and professional liability coverage. Contract structures range from firm one-year terms with renewal options to multi-year cooperative agreements with authorized wholesale distribution channels.

Geographic activity spans Texas, Florida, and the upper Midwest through multistate cooperative arrangements. The City of Tampa issued an IFB (26P00188) for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, seeking sealed bids for labetalol, epinephrine, adenosine, and diltiazem vials with a Small Local Business Enterprise sheltered market designation and a 5 percent bid discount for SLBE participation. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) closing March 26, 2026 for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers with pricing evaluation weighted 75 percent on competitiveness, effective July 1, 2026. The Texas HHS Commission posted an exploratory RFI (HHS0017013) in early April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future state-level demand for direct contracting outside traditional pharmacy benefit manager and wholesaler channels.